GBT Announces New Employment Inducement Grants
Global Blood Therapeutics (GBT) announced on July 1, 2021, that its compensation committee granted options to 23 new employees, allowing them to purchase a total of 9,600 shares of common stock at an exercise price of $37.34. Additionally, restricted stock units for an aggregate of 94,320 shares were awarded. These grants are part of GBT's Amended and Restated 2017 Inducement Equity Plan and comply with NASDAQ Listing Rule 5635(c)(4). Founded in 2011, GBT focuses on developing treatments for sickle cell disease.
- Awarding stock options and restricted units may enhance employee retention and motivation.
- The company continues to expand its workforce, signaling growth potential.
- None.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT’s board of directors granted 23 new employees options to purchase an aggregate of 9,600 shares of the company’s common stock with a per share exercise price of
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
What was announced by Global Blood Therapeutics on July 1, 2021?
How many shares were granted to employees by GBT?
What is the exercise price of the options granted by GBT?
Under which plan were the stock awards granted?
